Current Practice of Apalutamide in Patients with Metastatic Hormone-sensitive Prostate Cancer
Purpose: Apalutamide is an oral antiandrogen therapy currently licensed in the UK for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). This is based on randomised control trial evidence showing favourable overall survival with apalutamide plus ADT compared with ADT and placebo (HR for death 0.67, P = 0.005) [1]. A multicentre observational study in the UK, ADAPT-P, will look at real-world and patient-reported outcomes, as well as the healthcare professional perspective on apalutamide use.
Source: Clinical Oncology - Category: Radiology Authors: C. Thompson, J. Murray, G. Bucinskaite, K. Jones, L. Satchwell, Z. Rajan Source Type: research
More News: Cancer | Cancer & Oncology | Hormones | Oral Cancer | Prostate Cancer | Radiology | Study